Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC
Clinical trial NCT07120282 · RECRUITING
Trial details
- NCT number
- NCT07120282
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-28
- Primary completion
- 2029-08-15
- Enrollment
- 108
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.